<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2025-943
Date of Submission: 2025-07-04

This report was submitted by a Other Healthcare Professional from Newman-Alvarado Medical Center concerning patient ANON-PX-9601. The subject is a 38-year-old male with a significant medical history including type 2 diabetes, seasonal allergies, coronary artery disease, osteoarthritis. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities. 

Current medication review revealed the following suspected agent(s): Levothyroxine administered via the Intravenous route at a dosage of 355mg, initiated on 2025-04-26 for Hypothyroidism and discontinued on 2025-06-23; Sertraline administered via the Intravenous route at a dosage of 111mg, initiated on 2025-04-26 for Major depressive disorder and discontinued on 2025-06-23.

On approximately 2025-04-29, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Stevens-Johnson syndrome, Angioedema. The Stevens-Johnson syndrome was classified as Mild in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Recovering'. The Angioedema was classified as Mild in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Unknown'. 

CAUSALITY ASSESSMENT:
An evaluation of causality was performed. The assessment concluded the relationship was 'Probable'. Dechallenge/Rechallenge status was noted as: 'Negative dechallenge'. The on-site pharmacist concurred with the assessment during a routine case review. 

Reporter's Narrative Summary: Could word myself. Area they require customer son offer statement country.</data>
report_id: ADR-2025-943
report_date: '2025-07-04'
patient_details:
  patient_id: ANON-PX-9601
  gender: Male
  relevant_history:
  - type 2 diabetes
  - seasonal allergies
  - coronary artery disease
  - osteoarthritis
  age_at_reaction: 38
suspected_drugs:
- drug_name: Levothyroxine
  dosage: 355mg
  route_of_administration: Intravenous
  start_date: '2025-04-26'
  indication_for_use: Hypothyroidism
  end_date: '2025-06-23'
- drug_name: Sertraline
  dosage: 111mg
  route_of_administration: Intravenous
  start_date: '2025-04-26'
  indication_for_use: Major depressive disorder
  end_date: '2025-06-23'
adverse_reactions:
- symptom_name: Stevens-Johnson syndrome
  onset_date: '2025-04-29'
  severity: Mild
  outcome: Recovering
  intervention_required: false
- symptom_name: Angioedema
  onset_date: '2025-04-29'
  severity: Mild
  outcome: Unknown
  intervention_required: false
causality_assessment:
  assessment_conclusion: Probable
  dechallenge_rechallenge: Negative dechallenge
reporting_facility: Newman-Alvarado Medical Center
reporter_type: Other Healthcare Professional
notes: Could word myself. Area they require customer son offer statement country.
